| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-1647117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:N-(3,4-Dimethoxyphenyl)-3-(7-methoxybenzo[b]thiophen-2-yl)imidazo[1,2-b]pyridazin-6-amine
CAS:1627729-62-7
Purity:97% Package:10mg;25mg;50mg;100mg;250mg Remarks:BD01222611
|
Imidazo[1,2-b]pyridazin-6-amine, N-(3,4-dimethoxyphenyl)-3-(7-methoxybenzo[b]thien-2-yl)- manufacturers
- MLK-IN-1
-
- $2.00 / 100kg
-
2025-10-13
- CAS:1627729-62-7
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | Imidazo[1,2-b]pyridazin-6-amine, N-(3,4-dimethoxyphenyl)-3-(7-methoxybenzo[b]thien-2-yl)- Basic information |
| | Imidazo[1,2-b]pyridazin-6-amine, N-(3,4-dimethoxyphenyl)-3-(7-methoxybenzo[b]thien-2-yl)- Chemical Properties |
| density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 4.34±0.30(Predicted) | | form | Solid | | color | Light yellow to green yellow |
| | Imidazo[1,2-b]pyridazin-6-amine, N-(3,4-dimethoxyphenyl)-3-(7-methoxybenzo[b]thien-2-yl)- Usage And Synthesis |
| Uses | MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1[1]. | | Biological Activity | MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1[1].
MLK-IN-1 (100 nM; pre-treatment 20 mins HIV-1 Tat) promotes continued axonogenesis in the presence of Tat-activated microglia and protects against effects of HIV-Tat in vitro[1]. | | References | [1]. Val S. Goodfellow,et al.Mixed lineage kinase inhibitors and method of treatments. Patent US20140256733A1. |
| | Imidazo[1,2-b]pyridazin-6-amine, N-(3,4-dimethoxyphenyl)-3-(7-methoxybenzo[b]thien-2-yl)- Preparation Products And Raw materials |
|